A Dutch National Study to Facilitate Patient Access to Commercially Available Targeted Anticancer Drugs Evaluating Potential Efficacy in Advanced Cancers With Known Molecular Profiles

What this Trial Is About

Researchers are studying the use of targeted anticancer drugs in patients with advanced cancer who have specific molecular changes in their tumors. This study aims to describe how well these targeted drugs work and their side effects when prescribed based on a tumor's genetic or protein profile. It focuses on patients with advanced solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma who have no standard treatment options left and have acceptable health status and organ function. Participants receive targeted cancer drugs selected from a list of approved therapies matched to their tumor's molecular profile. A molecular tumor board and study coordinators help determine the best drug choice. Before treatment, patients provide a fresh tumor biopsy for genetic analysis. The study includes many drugs, including Panitumumab, Olaparib, Dabrafenib, and several others, some given alone or in combination, according to the tumor profile. Treatment eligibility and drug-specific criteria are confirmed before starting therapy. Throughout the study, participants are monitored for tumor response, disease stability, survival, and treatment side effects. Researchers collect data on tumor changes, progression-free survival, overall survival, and how long patients remain on treatment. Next generation sequencing on tumor samples provides additional biomarker information. The study continues to follow patients for up to one year after treatment to assess outcomes and safety.

The Drug Rediscovery Protocol (DRUP Trial)